OHCA Provider Letter 2019-20 Prior Authorization of Medications Used to Treat Lymphoma

As authorized by Oklahoma Administrative Code (OAC) 317:30-5-77.2, effective October 15, 2019, the Oklahoma Health Care Authority (OHCA) will require a prior authorization (PA) for the following medications: Adcetris® (brentuximab vedotin), Beleodaq® (belinostat), Calquence® (acalabrutinib), Folotyn® (pralatrexate), Istodax® (romidepsin), Poteligeo® (mogamulizumab-kpkc), Truxima® (rituximab-abbs), Zevalin® (ibritumomab tiuxetan), and Zolinza® (vorinostat).

If a SoonerCare member has a paid claim for one of these medications within the last 45 days, the medication will be “grandfathered”. A "grandfathered" drug that is obtained through the pharmacy claim system will automatically be prior authorized based on past claims.

Please view the Provider Letter in its entirety here: Provider Letter 2019-20.

Submit all comments by close of business, October 17, 2019, via the comment box below.




Name (optional)

Email (optional)



Please note that all comments must be reviewed and approved prior to posting. Approved comments will be posted Monday through Friday between the hours of 7:30 a.m. – 4 p.m. Any comments received after 4 p.m. will be posted on the following business day.